- •Tumour budding is not equivalent to tumour grade in colorectal cancer.
- •Both tumour grade and tumour budding are associated with aggressive tumour features.
- •Tumour budding outperforms tumour grade as a prognostic factor.
- •Both contribute different information and should be reported in colorectal cancer.
Tumour grade is traditionally considered in the management of patients with colorectal cancer. However, a large body of literature suggests that a related feature, namely tumour budding, may have a more important clinical impact. The aim of our study is to determine the correlation between tumour grade and tumour budding and their impact on patient outcome.
A retrospective collective of 771 patients with colorectal cancer were included in the study. Clinicopathological information included tumour grade (World Health Organisation 2010; G1, G2 and G3) and tumour budding evaluated as BD1, BD2 and BD3 and representing 0–4 buds, 5–9 buds and 10 or more buds per 0.785 mm2, respectively.
Tumour grade and tumour budding were correlated (p < 0.0001, percent concordance: 33.8%). Of the BD1 cases, 18.1% were of G3. Only two BD3 cases were G1. Both high tumour grade and tumour budding were associated with higher pT, lymph node metastasis, distant metastasis and lymphatic and venous vessel invasion (p < 0.01, all), but only tumour grade was additionally associated with right-sided tumour location and mucinous histology. Higher tumour budding led to worse overall (p = 0.0286) and disease-free survival (p = 0.001), but tumour grade did not. Budding was independent of tumour grade in multivariate analysis.
Tumour grade and tumour budding are distinct features, as recognised by their different clinicopathological associations, reflecting different underlying biological processes. Nonetheless, tumour budding seems to outperform tumour grade in terms of predicting disease-free survival.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Squamous cell epitheliuoma of the lip. A study of five hundred and thirty-seven cases.J Am Med Assoc. 1920; 74: 656-664
- The classification of cancer of the rectum.J Pathol Bacteriol. 1932; 616 (46): 6
- The grading and prognosis of carcinoma of the colon and rectum.Ann Surg. 1939; 109: 500-533
- A new prognostic classification of rectal cancer.Lancet. 1987; 1: 1303-1306
- The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases.Histopathology. 1986; 10: 437-459
- Degree of differentiation in colorectal adenocarcinomas: a multivariate analysis of the influence on survival.J Clin Pathol. 1988; 41: 532-537
- WHO classification of tumours.2010
- Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.Mod Pathol. 2017; 30: 1299-1311
- Japanese society for cancer of the C, rectum: Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.Int J Clin Oncol. 2018; 23: 1-34
- Protocol for the examination of specimens from patients with primary carcinoma of the Colon and Rectum.2017
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2017; 28: iv22-iv40
- Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.Br J Canc. 2016; 115: 831-840
- Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial.J Clin Oncol. 2019; 37: 1886-1894
- Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum.J Am Coll Surg. 1995; 180: 705-712
- Study of histopathologic parameters to define the prognosis of stage II colon cancer.Int J Colorectal Dis. 2019; 34: 905-913
- Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer.J Canc. 2019; 10: 1209-1215
- Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.J Pathol. 2007; 212: 260-268
- Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma.Hum Pathol. 2019; 87: 18-27
- Interobserver agreement in grading of colorectal cancers-findings from a nationwide web-based survey of histopathologists.Histopathology. 2008; 52: 494-499
- Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.Virchows Arch. 2015; 466: 485-493
Published online: March 19, 2020
Accepted: February 8, 2020
Received in revised form: February 3, 2020
Received: October 8, 2019
© 2020 Elsevier Ltd. All rights reserved.